Preparing a Prohost Letter dedicated to immunotherapy and the firms that are behind the promising novel approaches towards enabling the immune system to treat, or cure diseases if possible, we fell on other genius approaches. In recent Prohost Letters, we discussed the CAR T immunotherapy approach for the management of advanced, or metastatic cancers and in the upcoming Issue, which was due two days ago, we are discussing the immune checkpoint protein inhibitors that also enables the T cells to seek and neutralize cancer cells. While preparing to post the issue on our website, we fell on . . .